Literature DB >> 28062830

Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.

Jian Teng1,2,3, Cintia C da Hora1,2,3, Rami S Kantar1,2,3, Ichiro Nakano4, Hiroaki Wakimoto5, Tracy T Batchelor2,6, E Antonio Chiocca7, Christian E Badr1,2,3, Bakhos A Tannous1,2,3.   

Abstract

Background: Molecular profile of glioblastoma multiforme (GBM) revealed 4 subtypes, 2 of which, proneural and mesenchymal, have been predominantly observed, with the latter displaying a more aggressive phenotype and increased therapeutic resistance. Single-cell RNA sequencing revealed that multiple subtypes actually reside within the same tumor, suggesting cellular heterogeneity in GBM. Further, plasticity between these 2 subtypes is observed during tumor recurrence and in response to radiation therapy.
Methods: Patient-derived GBM stemlike cells were cultured as neurospheres. These cells were differentiated in serum by attaching to the culture dishes. The "floating" cells that were not attached/differentiated were harvested from the conditioned medium. The characteristics of these cells were studied with limiting dilution assays and immunofluorescence staining. Cell growth and nuclear factor-kappaB (NFkB) activation were monitored using bioluminescent assays as well as quantitative polymerase chain reaction and western blotting. In vivo tumorigenesis was evaluated in orthotopic xenograft models using bioluminescence imaging.
Results: Patient-derived GBM stemlike cells undergo differentiation by attaching to the culture dish in serum-containing medium. We observed that a small subset of these cells escape this adhesion/differentiation and grow as floating cells. These cells displayed enhanced cancer stem cell properties with a molecular and phenotypic mesenchymal signature, including resistance to radiation and targeted therapies, a more aggressive tumor formation, and NFkB activation.
Conclusion: Our results endorse inherent intratumor molecular subtype heterogeneity in glioblastoma and provide a valuable approach to study phenotypic plasticity, which could be applied to find novel therapeutic strategies to eradicate this aggressive tumor and can be extended to other cancer types.
© The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  cancer stem cells; differentiation; glioblastoma; intratumor heterogeneity; mesenchymal transition

Mesh:

Year:  2017        PMID: 28062830      PMCID: PMC5464448          DOI: 10.1093/neuonc/now253

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  36 in total

1.  Cancer stem cells and radiotherapy: new insights into tumor radioresistance.

Authors:  Maximilian Diehn; Michael F Clarke
Journal:  J Natl Cancer Inst       Date:  2006-12-20       Impact factor: 13.506

2.  A secreted luciferase for ex vivo monitoring of in vivo processes.

Authors:  Thomas Wurdinger; Christian Badr; Lisa Pike; Ruben de Kleine; Ralph Weissleder; Xandra O Breakefield; Bakhos A Tannous
Journal:  Nat Methods       Date:  2008-01-20       Impact factor: 28.547

3.  Acidic stress promotes a glioma stem cell phenotype.

Authors:  A B Hjelmeland; Q Wu; J M Heddleston; G S Choudhary; J MacSwords; J D Lathia; R McLendon; D Lindner; A Sloan; J N Rich
Journal:  Cell Death Differ       Date:  2010-12-03       Impact factor: 15.828

4.  MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.

Authors:  Brian J Gill; David J Pisapia; Hani R Malone; Hannah Goldstein; Liang Lei; Adam Sonabend; Jonathan Yun; Jorge Samanamud; Jennifer S Sims; Matei Banu; Athanassios Dovas; Andrew F Teich; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Peter A Sims; Peter Canoll
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

5.  Acid pH in tumors and its potential for therapeutic exploitation.

Authors:  I F Tannock; D Rotin
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

Review 6.  Brain mesenchymal stem cells: The other stem cells of the brain?

Authors:  Florence Appaix; Marie-France Nissou; Boudewijn van der Sanden; Matthieu Dreyfus; François Berger; Jean-Paul Issartel; Didier Wion
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

7.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Authors:  Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

8.  Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.

Authors:  Mario L Suvà; Esther Rheinbay; Shawn M Gillespie; Anoop P Patel; Hiroaki Wakimoto; Samuel D Rabkin; Nicolo Riggi; Andrew S Chi; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; Miguel N Rivera; Nikki Rossetti; Simon Kasif; Samantha Beik; Sabah Kadri; Itay Tirosh; Ivo Wortman; Alex K Shalek; Orit Rozenblatt-Rosen; Aviv Regev; David N Louis; Bradley E Bernstein
Journal:  Cell       Date:  2014-04-10       Impact factor: 41.582

Review 9.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

10.  An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.

Authors:  Esther Rheinbay; Mario L Suvà; Shawn M Gillespie; Hiroaki Wakimoto; Anoop P Patel; Mohammad Shahid; Ozgur Oksuz; Samuel D Rabkin; Robert L Martuza; Miguel N Rivera; David N Louis; Simon Kasif; Andrew S Chi; Bradley E Bernstein
Journal:  Cell Rep       Date:  2013-05-23       Impact factor: 9.423

View more
  25 in total

1.  Kinins in Glioblastoma Microenvironment.

Authors:  Mona N Oliveira; Barbara Breznik; Micheli M Pillat; Ricardo L Pereira; Henning Ulrich; Tamara T Lah
Journal:  Cancer Microenviron       Date:  2019-08-16

Review 2.  Conventional and advanced imaging throughout the cycle of care of gliomas.

Authors:  Gilles Reuter; Martin Moïse; Wolfgang Roll; Didier Martin; Arnaud Lombard; Félix Scholtes; Walter Stummer; Eric Suero Molina
Journal:  Neurosurg Rev       Date:  2021-01-07       Impact factor: 3.042

Review 3.  Metabolic heterogeneity and adaptability in brain tumors.

Authors:  Christian E Badr; Daniel J Silver; Florian A Siebzehnrubl; Loic P Deleyrolle
Journal:  Cell Mol Life Sci       Date:  2020-06-06       Impact factor: 9.261

4.  Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.

Authors:  Jian Teng; Seyedali Hejazi; Lotte Hiddingh; Litia Carvalho; Mark C de Gooijer; Hiroaki Wakimoto; Marco Barazas; Marie Tannous; Andrew S Chi; David P Noske; Pieter Wesseling; Thomas Wurdinger; Tracy T Batchelor; Bakhos A Tannous
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

5.  Investigation of the potential therapeutic effect of cationic lipoplex mediated fibroblast growth factor-2 encoding plasmid DNA delivery on wound healing.

Authors:  Gülşah Erel-Akbaba; Hasan Akbaba
Journal:  Daru       Date:  2021-09-07       Impact factor: 4.088

6.  Extracellular Vesicles Induce Mesenchymal Transition and Therapeutic Resistance in Glioblastomas through NF-κB/STAT3 Signaling.

Authors:  Markus W Schweiger; Mao Li; Alberta Giovanazzi; Renata L Fleming; Elie I Tabet; Ichiro Nakano; Thomas Würdinger; Ennio Antonio Chiocca; Tian Tian; Bakhos A Tannous
Journal:  Adv Biosyst       Date:  2020-06-09

7.  Obtusaquinone: A Cysteine-Modifying Compound That Targets Keap1 for Degradation.

Authors:  Christian E Badr; Cintia Carla da Hora; Aleksandar B Kirov; Elie Tabet; Romain Amante; Semer Maksoud; Antoinette E Nibbs; Evelyn Fitzsimons; Myriam Boukhali; John W Chen; Norman H L Chiu; Ichiro Nakano; Wilhelm Haas; Ralph Mazitschek; Bakhos A Tannous
Journal:  ACS Chem Biol       Date:  2020-05-08       Impact factor: 5.100

Review 8.  An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5.

Authors:  Tamara Lah Turnšek; Xuanmao Jiao; Metka Novak; Sriharsha Jammula; Gina Cicero; Anthony W Ashton; David Joyce; Richard G Pestell
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

Review 9.  Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.

Authors:  Bernarda Majc; Metka Novak; Nataša Kopitar-Jerala; Anahid Jewett; Barbara Breznik
Journal:  Cells       Date:  2021-01-29       Impact factor: 6.600

Review 10.  Current trends in mouse models of glioblastoma.

Authors:  Masafumi Miyai; Hiroyuki Tomita; Akio Soeda; Hirohito Yano; Toru Iwama; Akira Hara
Journal:  J Neurooncol       Date:  2017-10-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.